Solventum to hive off healthcare software business, raises profit forecast
Solventum said it will separate its health information systems software business, leaving MedSurg and Dental Solutions, as part of its turnaround. The unit accounted for 16.3% of 2025 sales. Solventum raised 2026 organic sales growth to 2.5% to 3% and adjusted profit per share to $7.10 to $7.20. Q2 adjusted EPS was $2.55 on revenue of $2.21B, beating LSEG estimates.
How this was made
The 30-second read
Why it matters
The company’s forecast raise is supported by strong wound care and sterilization demand, while the planned separation of health information systems aims to unlock value and enable distinct growth agendas.
Market read
A company-specific guidance upgrade combined with a concrete divestiture plan provides a fresh catalyst for valuation and positioning in med-tech turnaround trades.
What to watch
Traders may be underweighting the 16.3% sales contribution of the divested unit and the timeline/terms of the separation, which can affect near-term earnings quality and cash flow.
Background
Solventum is pursuing a turnaround and faced renewed pressure from Trian Fund Management to cut costs and hive off non-core businesses.
Ticker impact
Solventum plans to separate its health information systems business and raised 2026 organic sales and adjusted profit per share forecasts.
Likely positive bias for the next few sessions as traders price higher 2026 adjusted EPS and a clearer, more focused MedSurg and Dental portfolio.
The article discloses a fresh forecast raise (organic sales growth to 2.5% to 3%, adjusted EPS $7.10 to $7.20) and a specific separation of the health information systems unit, both actionable catalysts for valuation and positioning.
Market effects
Could support sentiment for hospital consumables and sterilization peers if investors view the separation as improving focus and execution.
Limited direct regional read-through; company is Minnesota-based with global hospital demand exposure.
Moderate, as the guidance raise and restructuring are company-specific but can influence European/US med-tech turnaround comps.
Counterpoint
The separation may be value-neutral if integration costs, transition disruption, or slower software monetization offsets the forecast uplift.
Key entities
- companySolventum
Hospital consumables and sterilization devices provider planning to separate its healthcare software business and raising 2026 guidance.
- activist investorTrian Fund Management
Pressed Solventum in early May to manage costs and hive off non-core businesses.
- executiveBryan Hanson
CEO who said separation can unlock value by enabling distinct growth agendas.
